Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results

Key Takeaways:

• Brii Bio’s HBV functional cure portfolio continued to advance throughout 2025
• ENSURE study data, published in Nature Medicine, highlight BRII-179’s potential
• Phase 2b ENRICH and ENHANCE trials are fully enrolled, with data expected in 2H 2026
• The Company strengthened its research capabilities under CSO Dr. Brian Johns
• A cash position of US$276.1 million supports ongoing and future HBV programs

Brii Bio’s 2025 Progress

Brii Biosciences (Brii Bio) concluded 2025 with a strong sense of momentum in advancing its portfolio of hepatitis B virus (HBV) treatments. According to the Company, 2025 was a period of “strong execution and strategic progress,” driven by the mission to improve functional cure outcomes for a condition that remains a critical global health concern.

ENSURE Study and Key Findings

Central to these updates is the Phase 2b ENSURE study. At the American Association for the Study of Liver Diseases (AASLD) meeting, Brii Bio presented 24-week post end of treatment (EOT) follow-up data from Cohort 4, simultaneously published in Nature Medicine. These findings underscore the potential of BRII-179 to support functional cures for HBV across a diverse range of patient populations.

Based on insights from Cohort 4, Brii Bio amended the ENHANCE study protocol to explore an alternative triple combination regimen designed to maintain efficacy while potentially reducing the duration of pegylated interferon alpha (PEG-IFNα) treatment.

ENRICH and ENHANCE Studies

The Company’s two confirmatory Phase 2b studies, ENRICH and ENHANCE, are now fully enrolled, marking another milestone in Brii Bio’s push toward higher HBV functional cure rates. Results from these trials are expected in the second half of 2026, positioning the Company for a series of significant data releases that could further reshape the HBV treatment landscape.

Discovery and Research Expansion

Beyond clinical trials, Brii Bio has deepened its research capabilities, led by Chief Scientific Officer Dr. Brian Johns, who joined in 2024. The Company has assembled an experienced discovery team with in-house wet lab operations in Beijing and Shanghai. This infrastructure utilizes China’s dynamic drug discovery ecosystem, aiming to broaden Brii Bio’s early-stage pipeline and sustain value creation.

Looking ahead, Brii Bio intends to outline its overarching discovery strategy and pipeline progress in greater detail within 2026, signaling further innovation on the horizon.

Financial Health and Management

From a financial perspective, Brii Bio maintains a strong capital foundation. As of December 31, 2025, the Company held US$276.1 million in cash. This position reflects targeted and disciplined financial decisions, including strategic adjustments to the operating structure and executive compensation.

According to Chief Executive Officer and Chairman Dr. Zhi Hong, “2025 was a year of strong execution for Brii Bio as we continued to advance our HBV functional cure strategy. The publication of our ENSURE study data in Nature Medicine underscores the scientific rigor behind our clinical approach and our long-standing commitment to improving outcomes for patients with chronic hepatitis B.”

With solid financials and steady program momentum, Brii Bio remains focused on sustainable growth, culminating in both near-term study readouts and long-term discoveries that aim to address diseases with high unmet medical need.